東華大學圖書館 |

Language: English

Help

回圖書館首頁

手機版館藏查詢

Back

Switch To: Labeled | MARC Mode | ISBD

Retinal degenerative diseases = mech...

Bowes Rickman, Catherine.

Linked to FindBook

Google Book

Amazon

博客來

Retinal degenerative diseases = mechanisms and experimental therapy /

Record Type:	Electronic resources : Monograph/item
Title/Author:	Retinal degenerative diseases/ edited by Catherine Bowes Rickman ... [et al.].
Reminder of title:	mechanisms and experimental therapy /
other author:	Bowes Rickman, Catherine.
Published:	Cham :Springer International Publishing : : 2016.,
Description:	lv, 824 p. :ill., digital ;24 cm.
Contained By:	Springer eBooks
Subject:	Retinal degeneration. -
Online resource:	http://dx.doi.org/10.1007/978-3-319-17121-0
ISBN:	9783319171210$q(electronic bk.)

Retinal degenerative diseases = mechanisms and experimental therapy /
Retinal degenerative diseasesmechanisms and experimental therapy /[electronic resource] :edited by Catherine Bowes Rickman ... [et al.]. - Cham :Springer International Publishing :2016. - lv, 824 p. :ill., digital ;24 cm. - Advances in experimental medicine and biology,v.8540065-2598 ;. - Advances in experimental medicine and biology ;946..

Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who spoke and presented posters at the meeting contributed to this volume. The Symposium addressed the blinding diseases of inherited retinal degenerations, which have no effective treatments, and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations are included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances are presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those are reported at the RD2014 meeting and included in this volume.

ISBN: 9783319171210$q(electronic bk.)

Standard No.: 10.1007/978-3-319-17121-0doiSubjects--Topical Terms:

894561
Retinal degeneration.

LC Class. No.: RE661.D3

Dewey Class. No.: 617.735

Retinal degenerative diseases = mechanisms and experimental therapy /
LDR:03603nmm a2200313 a 4500 001 2028736
003 DE-He213
005 20160718144933.0
006 m d
007 cr nn 008maaau
008 160908s2016 gw s 0 eng d
020 $a 9783319171210$q(electronic bk.)
020 $a 9783319171203$q(paper)
024 7 $a 10.1007/978-3-319-17121-0 $2 doi
035 $a 978-3-319-17121-0
040 $a GP $c GP
041 0 $a eng
050 4 $a RE661.D3
072 7 $a MJQ $2 bicssc
072 7 $a MED063000 $2 bisacsh
082 0 4 $a 617.735 $2 23
090 $a RE661.D3 $b R438 2016
245 0 0 $a Retinal degenerative diseases $h [electronic resource] : $b mechanisms and experimental therapy / $c edited by Catherine Bowes Rickman ... [et al.].
260 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2016.
300 $a lv, 824 p. : $b ill., digital ; $c 24 cm.
490 1 $a Advances in experimental medicine and biology, $x 0065-2598 ; $v v.854
520 $a Contains the proceedings of the XVI International Symposium on Retinal Degeneration (RD2014), held July 13-18, 2014 at the Asilomar Conference Center in Pacific Grove, California. A majority of those who spoke and presented posters at the meeting contributed to this volume. The Symposium addressed the blinding diseases of inherited retinal degenerations, which have no effective treatments, and age-related macular degeneration, which has no cures, despite the fact that it is an epidemic among the elderly, with 1 in 3-4 affected by the age of 75. The RD2014 Symposium focused on the exciting new developments aimed at understanding these diseases and providing therapies for them. The volume presents representative state-of-the-art research in almost all areas of retinal degenerations, ranging from cytopathologic, physiologic, diagnostic and clinical aspects; animal models; mechanisms of cell death; molecular genetics; and developing potential therapeutic measures such as gene therapy and neuroprotective agents for potential pharmaceutical therapy; and several sight restoration approaches, including optogenetics. While advances in these areas of retinal degenerations are included, several new topics either were in their infancy or did not exist at the time of the last RD Symposium, RD2012. These include many new developments in sight restoration using optogenetics, retinal or RPE cell transplantation, stem cell approaches and visual prosthetic devices. In addition, major advances are presented in other basic mechanisms in age-related macular degeneration, several new aspects of gene and antioxidant therapy, and revolutionary new imaging and functional testing that will have a huge impact on the diagnosis and following the course of retinal degenerations, as well as to provide new quantitative endpoints for clinical trials. The retina is an approachable part of the central nervous system (CNS), and there is a major interest in neuroprotective and gene therapy for CNS diseases and neurodegenerations, in general. It should be noted that with successful and exciting initial clinical trials in neuroprotective and gene therapy, including the restoration of sight in blind children, the retinal degeneration therapies are leading the way towards new therapeutic measures for neurodegenerations of the CNS. Many of the successes recently reported in these areas of retinal degeneration sprang from collaborations established at previous RD Symposia, and many of those are reported at the RD2014 meeting and included in this volume.
650 0 $a Retinal degeneration. $3 894561
650 1 4 $a Medicine & Public Health. $3 890906
650 2 4 $a Ophthalmology. $3 862704
650 2 4 $a Neurosciences. $3 588700
650 2 4 $a Immunology. $3 611031
700 1 $a Bowes Rickman, Catherine. $3 2179309
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer eBooks
830 0 $a Advances in experimental medicine and biology ; $v 946. $3 1565434
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-17121-0
950 $a Biomedical and Life Sciences (Springer-11642)